ABRYSVO is a vaccine indicated for:
- the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people 60 years of age and older.
- pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
Each 0.5ml reconstituted dose contains: RSV subgroup A stabilised prefusion F protein 60 µg, RSV subgroup B stabilised prefusion F protein 60 µg, tromethamine, tromethamine hydrochloride, sucrose, mannitol, polysorbate 80, sodium chloride & traces of hydrochloric acid.
